The Alzheimer Society Research Portal connects researchers with Canadians looking to participate in research studies. On this website, find active studies that you can participate in to help advance research on dementia.
Quick Searches
Selecting one or more of the options below will update the content below.
- Observational StudyOnline
What is this Study about?
Alert systems such as United States’ Silver Alert and Scotland’s Purple Alert support first responders in locating missing persons with dementia. In Canada, provinces are responsible for Silver Alerts. To date, Alberta and Manitoba amended Missing Persons Acts, but have no Silver Alerts. British Columbia has a citizen-led Silver Alert, yet no provincial legislation. This study examines how policies and programs for alert systems are developed and implemented in Canada, Scotland, and the United States. Findings will inform policies and implementation of alert systems to optimize the safety and well-being of people living with dementia at risk of going missing.
Eligibility Criteria
have experience or interest in using Silver Alert to locate missing persons with dementia and are a/an:
• Person living with dementia
• Care partner
• Alzheimer Society staff
• First responder
• Service provider
• Technology developer
• Policy maker
Recruitment End Date
- Clinical TrialIn-Person
What is this Study about?
The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (including mild cognitive impairment [MCI] and mild dementia due to AD) of 2 dose levels of GSK4527226 compared to placebo.
Eligibility Criteria
Age 50 - 85
Mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease
Must have a study partnerRecruitment End Date
- Clinical TrialIn-Person
What is this Study about?
The purpose of this study is to assess the efficacy of an oral medication, IGC-AD1 that is a natural THC-based (Tetrahydrocannabinol) formulation, administered in micro doses, twice a day, on symptomatological Agitation, in patients with mild to severe dementia from Alzheimer's.
Eligibility Criteria
60+
Diagnosis of Alzheimer's disease
Must have a study partnerRecruitment End Date
- Observational StudyIn-Person
What is this Study about?
Our study titled "Investigating the Role of Quantitative Susceptibility Mapping and Oxygen Extraction Fraction as Advanced Neuroimaging Biomarkers in Alzheimer's Disease" aims to develop non-invasive diagnostic biomarkers for Alzheimer's Disease (AD). We focus on evaluating the potential of QSM and OEF to differentiate between AD, Mild Cognitive Impairment (MCI), and Cognitively Unimpaired populations and to predict amyloid and tau pathology, using a Systems Biology approach. Leveraging the McGill University's TRIAD cohort, the study utilizes advanced imaging and machine learning to predict amyloid and tau presence, which could transform AD diagnostics and treatment. Methodologically, it involves preprocessing neuroimaging data and employing machine learning classifiers to analyze these features. The anticipated outcomes include validating QSM and OEF as non-invasive biomarkers for AD, establishing their correlation with amyloid and tau proteins, and developing predictive models for clinical decision-making, potentially resulting in significant advancements in AD diagnostics.
Eligibility Criteria
Are a member of the TRIAD cohort at McGill University, falling within one of the following categories: young control, cognitively unimpaired, mild cognitive impairment, or Alzheimer's Disease.
Are willing and able to undergo advanced neuroimaging techniques including MRI and PET without contraindications.
Have not had any significant neurological conditions (other than AD for the AD group) that might interfere with the results of the study.
Have no metal implants, devices, or other conditions that may contraindicate or distort MRI imaging.
Are not currently participating in other clinical trials or studies that involve interventions which might interfere with the results of this study.
Are able and willing to provide informed consent for participation in the study or have a legally authorized representative who can do so.
Do not have a history of substance abuse or other conditions that might confound the imaging and cognitive data.
Have not undergone any significant head trauma or surgery in the past 6 months.
Are not pregnant or planning to become pregnant during the duration of the study.
Are willing to comply with all study-related procedures, imaging sessions, and follow-up evaluations.
Ability to speak English and French
Recruitment End Date
- Observational StudyOnline & In-Person
What is this Study about?
The purpose of this study is to assess whether a virtually-delivered healthy lifestyle intervention (over Zoom) is feasible for individuals who feel that their memory or thinking is declining.
Eligibility Criteria
-Are between the age of 65-85
-Are concerned about your memory and other thinking abilities
-Have access to internet at home
-Are a resident of Saskatchewan, Manitoba, Ontario, or Quebec
Recruitment End Date
- Observational StudyQuebec
What is this Study about?
We are interested in visuospatial abilities in patients with possible or probable Alzheimer’s disease at an early stage. The experiment will be carried out online on a computer in your home, over three years
Eligibility Criteria
- Person with mild cognitive impairment with no other neurological diseases
OR - Healthy adults (aged 65+)
Recruitment End Date
- Person with mild cognitive impairment with no other neurological diseases
- Observational StudyCanada-Wide (all provinces)
What is this Study about?
The aim is to better understand the cognitive strengths and difficulties related to visuospatial skills among people with Mild Cognitive Impairment and/or early Alzheimer's Disease through cognitive tasks.
Eligibility Criteria
- Adults with MCI and/or AD
OR - Healthy, 40+ Years, with parent diagnosed with AD
Recruitment End Date
- Adults with MCI and/or AD
Alzheimer Society of Canada
20 Eglinton Avenue West, 16th Floor
Toronto, Ontario M4R 1K8
Information and Referral Line: 1-855-705-4636
Email: [email protected]
Charity registration number: 11878 4925 RR0001
Follow us: